Skip to main content
Clinical Trials/ACTRN12612000666820
ACTRN12612000666820
Recruiting
Phase 4

A prospective, open-label clinical trial, to evaluate the efficacy of intravitreal Aflibercept for the treatment of previously treated exudative age-related macular degeneration

Andrew Chang0 sites70 target enrollmentJune 21, 2012

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Andrew Chang
Enrollment
70
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 21, 2012
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Andrew Chang

Eligibility Criteria

Inclusion Criteria

  • 1\. Ability to provide informed consent and complying with the study assessments who are the
  • 2\. Age 50 years or older
  • 3\. Choroidal neovascularization secondary to age\-realted macular degeneration
  • 4\. Best corrected vision between 6/6 to 6/60 on EDTRS chart
  • 5\. Presence of subretinal fluid or cystic intraretinal oedema on optical coherence tomography after at least 4 anti\-VEGF treatments within minimum of 6 months and maximum of 3 years before enrollment of the study
  • 6\. Documentation of the presence of subretinal fluid or cystoid oedema less than 30 days since last treatment.

Exclusion Criteria

  • 1\. Pregnancy or lactation
  • 2\. Premenopausal women not using contraception
  • 3\. Prior anti\-VEGF injection in the study eye within 30 days of baseline
  • 4\. Prior treatment with PDT (Visudyne) within 90 days of baseline and more than 6 prior PDT treatments
  • 5\. Significant subretinal fibrosis or atrophy
  • 6\. Prior treatment with triamcinolone in the study eye within 6 months of baseline
  • 7\. Intraocular surgery in the study eye within 2 months of baseline
  • 8\. Prior vitrectomy or other surgical intervention for age\-realted macular degeneration in the study eye
  • 9\. Current vitreous haemorrhage or inflammation in the study eye
  • 10\. Uncontrolled glaucoma I the study eye. Intraocular pressure greater than 30mmHg on maximal medical therapy

Outcomes

Primary Outcomes

Not specified

Similar Trials